| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We examined neuroprotective effects of serotonin-1A receptor agonist 8-OH-DPAT on progressive motor neuron degeneration in amyotrophic lateral sclerosis (ALS) model mice and in primary culture cells. The pre-treatments of 8-OH-DPAT prior to onset of motor symptoms delayed disease onset. The chronic post-treatments of the drug after the onset significantly inhibited disease progression and showed protective effects on motor neuron loss in the cervical and lumber spinal cords in the ALS models. Furthermore, we revealed that the neuroprotective effects are based, in part, on expression and release of metallothionein in/from astrocytes via serotonin-1A receptors and sequent activation of transcription factor Nrf2.
|
